Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Merck & Co., Inc. (MRK) vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock (TTWO) Price & Performance

Merck & Co., Inc.Trade
TAKE-TWO INTERACTIVE SOFTWARE, INC Common StockTrade

Price performance (Past 24H)

Key statistics

Merck & Co., Inc. vs TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock — how do they compare? Merck & Co., Inc. trades at $132.9 (market cap $321.77B), while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock trades at $243 (market cap $46.84B). The key difference: Merck & Co., Inc. is far larger — about 6.9× TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock's market cap, and Merck & Co., Inc. pays a 2.61% dividend while TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock pays none. Which is the better fit depends on your goals.

MRKTTWO
Market Cap
$321.77B$46.84B
Sector
HealthMedia
52-Week High
$131.84$262.29
52-Week Low
$77.60$189.69
Enterprise Value
$368.53B$47.96B
Dividend Yield
2.61%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Merck & Co., Inc.

Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue reached $65.01B in 2025, and net income margin improved to 28.07%. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid a competitive pharmaceutical landscape.

The outlook for MRK is positive, supported by analyst consensus favoring a buy rating (67.57%) and a price target of $140.36. Key opportunities include pipeline expansion through M&A and solid cash flow generation. Risks involve high valuation multiples, such as a P/E of 104.34, and potential integration challenges from acquisitions. Investors should weigh growth prospects against elevated earnings expectations and market volatility.

TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock

Take-Two Interactive (TTWO) trades at $243.60, down 3.93% over 24 hours, with a bullish technical signal from moving averages and support near $240. The company reported Q1 2026 EPS of $0.80, beating estimates, but faces fundamental challenges with a net income margin of -4.79% and negative ROE of -9.04%. Recent news highlights strong GTA VI pre-orders as a key catalyst, with FY2027 net bookings guidance maintained at $8-$8.2 billion (company earnings report, August 7, 2026).

Outlook is optimistic due to GTA VI's November 2026 launch potential, but risks include high debt levels (debt-to-asset ratio of 39.87% in 2025) and consistent net losses. Analyst consensus is strongly bullish with a $300.55 price target, suggesting 23% upside from current levels if execution improves.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Merck & Co., Inc.

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.

Read more on MRK

About TAKE-TWO INTERACTIVE SOFTWARE, INC Common Stock

Found in 1993, Take-Two consists of three wholly owned labels, Rockstar Games, 2K, and Zynga. The firm is one of the world's largest independent video game publishers on consoles, PCs, smartphones, and tablets. Take-Two's franchise portfolio is headlined by Grand Theft Auto (345 million units sold) and contains other well-known titles such as NBA 2K, Civilization, Borderlands, Bioshock, and Xcom. Zynga mobile titles include Farmville, Empires & Puzzles, and CSR Racing.

Read more on TTWO